Form 4: Vertex Pharmaceuticals EVP, COO Stuart A. Arbuckle Reports Stock Transaction
SEC Form 4 Filing
Stuart A. Arbuckle, EVP and COO of Vertex Pharmaceuticals, reports a transaction involving common stock, including the disposition of shares to cover tax obligations.
Summary
- On February 10, 2025, Stuart A. Arbuckle, the EVP and COO of Vertex Pharmaceuticals, reported a transaction involving the company's common stock.
- 3,220 shares were disposed of at a price of $467.98 to cover tax obligations.
- Following the transaction, Arbuckle directly owns 69,543 shares of Vertex Pharmaceuticals common stock.
- He also indirectly owns 140 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing simply reports a routine stock transaction by an executive to cover tax obligations. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment with company performance.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
- Similar filings are common across the pharmaceutical industry, with executives at companies like Amgen, Gilead Sciences, and Pfizer regularly reporting their transactions in company stock.
- The specifics of each transaction, such as the number of shares traded and the price, are unique to each individual and company, reflecting their individual financial strategies and the company's stock performance.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it is a routine sale of shares by an executive.
- The filing provides transparency to stakeholders regarding insider transactions, which can influence investor confidence.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of the stock transaction (disposal of shares). |
| 02/12/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, VRTX, Vertex Pharmaceuticals, Stock Transaction, Insider Trading, Stuart A. Arbuckle, EVP, COO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.